Diabetes is a chronic condition characterized by high blood sugar levels, which, if left uncontrolled, can lead to serious health complications. HbA1c is a critical marker that reflects long-term glucose control. Managing HbA1c effectively is crucial in diabetes care, as it reduces the risk of complications.
Balancing the latest innovations, such as advanced medications and technologies, with conventional approaches like lifestyle modifications and established therapies is key. This integrated approach offers patients personalized, comprehensive care, enhancing their ability to maintain optimal HbA1c levels and improve overall well-being while minimizing diabetes-related risks
Evolving Landscape of Diabetes Management: Balancing Latest and Conventional Approaches for HbA1c Control
By Prof. David Matthews
Prof. David Matthews is the recent past President of the European Association for the Study of Diabetes (EASD). He is the Emeritus Founding Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism. Emeritus Professor of Diabetic Medicine at the University of Oxford. Past NIHR Senior Investigator and Founding Director of the Oxford Health Alliance. Emeritus Fellow of Harris Manchester College, Oxford. His research interests include personalized medicine, the etiopathology of non-insulin-dependent diabetes, therapeutic agents in type 2 diabetes, mathematical modelling of insulin resistance, homeostatic model assessment of beta-cell function and insulin resistance (HOMA and iHOMA), the incretin axis and glucagon-like peptide-1, pulsatile insulin secretion, and the global obesity epidemic. Dr. David Matthews was on the steering committee of the UKPDS. He gave the Banting Memorial Lecture at Diabetes UK (‘Type 2 diabetes: the Black Death of the 21st century’), lectures widely on therapeutics, personalised medicine, and mathematical modelling. He chaired the EASD/ADA group that produced the international guidelines on the treatment of type 2 diabetes – both in 2012 and in 2015. He is co-chair of the CANVAS and CANVAS-R phase III studies investigating cardiovascular outcomes with canagliflozin. He is co-chair of the VERIFY trial which examined the use of vildagliptin early in T2DM to avoid primary therapeutic failure. He has authored more than 320 academic peer-reviewed publications.